Applied Health Economics and Health Policy

, Volume 9, Issue 4, pp 259–273

Cost effectiveness of secondary vs tertiary prevention for post-menopausal osteoporosis

Original Research Article

DOI: 10.2165/11587360-000000000-00000

Cite this article as:
Mueller, D. & Gandjour, A. Appl Health Econ Health Policy (2011) 9: 259. doi:10.2165/11587360-000000000-00000

Abstract

Background

The aging of the population is likely to increase the number of osteoporosis-related fractures, such as hip fractures, and hence the economic burden for society. Therefore, strategies to identify women at increased risk are of major interest.

Objective

The aim of this study was to determine the cost effectiveness of preventive services for osteoporosis, comparing secondary plus tertiary prevention (SP/TP) versus tertiary prevention (TP) alone in post-menopausal women in Germany.

Methods

A cost-utility analysis and a budget-impact analysis were performed from the perspective of the German statutory health insurance (SHI). A Markov model simulated costs and benefits discounted at 3% over a lifetime horizon.

Results

Cost effectiveness of TP compared with no screening was €669, €477 and €385 per QALY for women aged 60, 70 and 80 years, respectively (year 2010 values). In women aged 50 years, TP dominated no prevention. Cost effectiveness of SP/TP compared with TP was €4543, €19 791, €8670 and €3368 for women aged 50, 60, 70 and 80 years, respectively. SP/TP resulted in additional costs of €109 million or 0.10% of the SHI’s annual budget (TP alone = €8 million).

Conclusion

Compared with TP, a strategy based on SP/TP appears to be more expensive but more effective in each age group. Given that cost effectiveness seems acceptable, allocation of resources to SP/TP to decrease post-menopausal osteoporotic fracture risk may be justified.

Supplementary material

40258_2012_9040259_MOESM1_ESM.pdf (90 kb)
Supplementary material, approximately 92 KB.

Copyright information

© Adis Data Information BV 2011

Authors and Affiliations

  1. 1.Health Economics, Institute for Health Economics and Clinical EpidemiologyThe University Hospital of Cologne (AöR)KölnGermany
  2. 2.Pennington Biomedical Research Center/Louisiana State UniversityLouisianaUSA